ClinicalTrials.gov
ClinicalTrials.gov Menu

Cannabis Oil for Chronic Non-Cancer Pain Treatment (CONCEPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03635593
Recruitment Status : Not yet recruiting
First Posted : August 17, 2018
Last Update Posted : November 12, 2018
Sponsor:
Information provided by (Responsible Party):
Ramesh Zacharias, Hamilton Health Sciences Corporation

Brief Summary:
Cannabis is being prescribed medically for chronic non-cancer pain despite limited evidence whether or not it works to reduce average pain in patients with chronic non-cancer pain. The cannabis plant (Cannabis sativa, Cannabis indica) consists of several hundred compounds of which, approximately 70 of which are thought to be active. The two active cannabinoids of interest in this trial are tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). The goal of this trial is to determine whether CBD or CBD+THC reduces the average pain in participants with chronic non-cancer pain. The investigators also aim to determine whether CBD or CBD+THC is associated with a reduction in pain severity, pain interference, anxiety, depression, insomnia, opioids and use of benzodiazepines, analgesics, antidepressants, anxiolytics, or hypnotics amongst chronic non-cancer pain patients or an increase in physical functioning, physical health related role limitations, social functioning, mental functioning.

Condition or disease Intervention/treatment Phase
Chronic Non-cancer Pain Drug: CBD Drug: CBD+THC Other: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 309 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cannabis Oil for Chronic Non-CancEr Pain Treatment [CONCEPT] - Alpha (α): A Randomized Controlled Trial
Estimated Study Start Date : January 1, 2019
Estimated Primary Completion Date : January 30, 2021
Estimated Study Completion Date : January 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Arm Intervention/treatment
Active Comparator: CBD
10mg capsules Cannabidiol (CBD)
Drug: CBD
Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.

Active Comparator: CBD+THC
10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
Drug: CBD+THC
Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.

Placebo Comparator: Placebo
10mg capsules placebo
Other: Placebo
Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.




Primary Outcome Measures :
  1. Average Pain Score [ Time Frame: 12 weeks after Treatment (Week 16 of trial) ]
    Relative change in Average Pain Score measured by the Average Pain Score ( 0=No Pain and 10=Pain as bad as you can imagine) from the Numeric Rating Scale


Secondary Outcome Measures :
  1. Pain Severity Score [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Decrease in Pain Severity Score measured by composite of 4 pain items (worst, least, average, now with 0=No Pain and 10=Pain as bad as you can imagine) (mean severity score) from the Brief Pain Inventory

  2. Pain Intensity Score [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Improved Pain Intensity Score measured by mean of 7 severity items (general, activity, walking, work, mood, enjoyment of life, relations with others and sleep with 0=No Pain and 10=Pain as bad as you can imagine) from the Brief Pain Inventory

  3. Physical Functioning Score [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Increase in Physical Functioning Score measured by the SF-36V2. 10 items in this scale represent levels and kinds of limitations between the extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling or stooping and walking moderate distances. One self-care item is included to represent limitations in self-care activities. This scale captures both the presence and existent of physical limitations using a three-level response continuum. Low scores indicate significant limitations in performing physical activities, while high scores reflect little or no such limitations.

  4. Mental Health Score [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Increase in Mental Health (MH) Score measured by the SF-36V2. This 5-item scale includes one or more items from each of four major mental health dimensions (anxiety, depression, loss of behavioral/emotional control, and psychological wellbeing). Low scores on MH are indicative of frequent feelings of nervousness and depression, while high scores indicate feelings of peace, happiness, and calm all or most of the time.

  5. Social Functioning Score [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Increase in Social Functioning (SF) Score measured by the SF-36V2. This 2-item scale assesses health-related effects on quantity and quality of social activities, asking specifically either physical or emotional problems on social activities. The degree to which physical and emotional problems interfere with normal social actives increases with decreasing SF scores. The lowest score is related to extreme or frequent interference with normal social actives due to physical and emotional problems; the highest score indicates that the individual performs normal social activities without interference from physical or emotional problems..

  6. Physical Health-related Role Limitations [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Decrease in Physical Health-related Role Limitations measured by the SF-36V2. This 4-item scale covers an array of physical health-related role limitations, including a) limitations in the kind of work or other usual activities, b) reduction in the amount of time spend on work or other usual activities, c) difficulty performing work or other usual activities, and d) accomplishing less. Low scores on this scale reflect problems with work or other actives as a result of physical problems. High scores indicate little or no problems with work or other daily activities.

  7. Depression Score [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Improvement in Depression score measured by the Patient Health Questionnaire (PHQ-9). The PHQ-9 depression severity is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively. PHQ-9 total score for the nine items ranges from 0 to 27. Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.

  8. Anxiety Score [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Improvement in Depression score measured by the Generalized Anxiety Disorder (GAD-7). This is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively. GAD-7 total score for the seven items ranges from 0 to 21. Scores of 5, 10, and 15 represent cutpoints for mild, moderate, and severe anxiety, respectively.

  9. Sleep Quality [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Improvement in the Sleep Quality Score measured by the Insomnia Severity Index (ISI).Improvement in the Sleep Quality Score measured by the Insomnia Severity Index (ISI). Seven question added to get total score (0-28). Score of 0-7 has no clinically significant insomnia, 8-14 subthreshold insomnia, 15-21 clinical insomnia - moderate severity and 22-28 clinical insomnia - severe.

  10. Pain Medication [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Decrease in prescription pain medication use. Measured by recording initial and changes in prescription medication names, dose and frequency

  11. Other non-pain prescription medications [ Time Frame: Baseline, week 4, 8, 12 and 16 ]
    Decrease in other no-pain prescription medications. Measured by recording initial and changes in non-prescription medications names, dose and frequency

  12. Average Pain Score [ Time Frame: Baseline, week 4, 8 and 12 ]
    Relative change in Average Pain Score measured by the Average Pain Score ( 0=No Pain and 10=Pain as bad as you can imagine) from the Numeric Rating Scale



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   26 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age >25
  • Average pain score in past week of ≥ 4/10.

Exclusion Criteria:

  • Personal history of bipolar disorder
  • Personal or family history (first degree relative - parent of sibling) of psychotic disorders (e.g., schizophrenia)
  • Active cancer (an individual undergoing active cancer chemotherapy, radiation or surgical treatment and is deemed to not be in remission as per an oncologist's report)
  • Intention to travel internationally during the trial
  • Uncontrolled diabetes (A1C > 11)
  • Cannabis use in the past 4 weeks (recreational or medicinal)
  • Current use of illicit drugs (e.g., cocaine)
  • Current use of non-prescription opioids
  • Unable to read and write in English
  • Women who are currently pregnant or breast-feeding; or women of child-bearing age who plan to become pregnant during the trial period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03635593


Contacts
Contact: Lisa L Patterson, BA 905-978-7908 pattersl@hhsc.ca

Locations
Canada, Ontario
Michael G. DeGroote Pain Clinic Not yet recruiting
Hamilton, Ontario, Canada, L8N 3Z5
Contact: Lisa L Patterson    905-978-7861    pattersl@hhsc.ca   
Toronto Poly Clinic Not yet recruiting
Toronto, Ontario, Canada
Contact: Ashley Villarruel       ashley@tpclinic.com   
Sponsors and Collaborators
Hamilton Health Sciences Corporation

Responsible Party: Ramesh Zacharias, Medical Director, Hamilton Health Sciences Corporation
ClinicalTrials.gov Identifier: NCT03635593     History of Changes
Other Study ID Numbers: MGD-011-20180805
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: November 12, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No